Matching articles for "Rapivab"

Antiviral Drugs for Influenza for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table...
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu. None of the drugs that are FDA-approved for treatment of influenza have clinically relevant antiviral activity against SARS-CoV-2.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):185-90 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza for 2022-2023 (online only)

   
The Medical Letter on Drugs and Therapeutics • November 28, 2022;  (Issue 1664)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2022-2023
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e1-5 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • October 3, 2022;  (Issue 1660)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):153-7 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • January 10, 2022;  (Issue 1641)
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral...
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at higher risk for complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2022 Jan 10;64(1641):2-7 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)

   
The Medical Letter on Drugs and Therapeutics • January 10, 2022;  (Issue 1641)
...
View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022
Med Lett Drugs Ther. 2022 Jan 10;64(1641):e1-5 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • October 4, 2021;  (Issue 1634)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):153-7 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza for 2020-2021

   
The Medical Letter on Drugs and Therapeutics • November 2, 2020;  (Issue 1610)
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table...
Influenza is generally a self-limited illness, but complications such as pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza this season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):169-73 | Show Full IntroductionHide Full Introduction

Comparison Chart: Antiviral Drugs for Influenza (online only)

   
The Medical Letter on Drugs and Therapeutics • November 2, 2020;  (Issue 1610)
...
View the Comparison Chart: Antiviral Drugs for Influenza
Med Lett Drugs Ther. 2020 Nov 2;62(1610):e176-80 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Influenza

   
The Medical Letter on Drugs and Therapeutics • January 13, 2020;  (Issue 1589)
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase inhibitors...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur. FDA-approved antiviral drugs for influenza are listed in Table 2. The neuraminidase inhibitors oseltamivir (Tamiflu, and generics), which is taken orally, and zanamivir (Relenza), which is inhaled, are approved for prophylaxis and treatment of acute uncomplicated influenza. The IV neuraminidase inhibitor peramivir (Rapivab) and the oral polymerase acidic (PA) endonuclease inhibitor baloxavir marboxil (Xofluza) are approved only for treatment. All of these drugs are active against both influenza A and influenza B viruses. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2020 Jan 13;62(1589):1-4 | Show Full IntroductionHide Full Introduction

Expanded Table: Antiviral Drugs for Influenza (online only)

   
The Medical Letter on Drugs and Therapeutics • January 13, 2020;  (Issue 1589)
...
View the Expanded Table: Antiviral Drugs for Influenza
Med Lett Drugs Ther. 2020 Jan 13;62(1589):e9-10 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza

   
The Medical Letter on Drugs and Therapeutics • January 14, 2019;  (Issue 1563)
Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is...
Antiviral drugs can be used for treatment and prophylaxis of seasonal influenza (see Table 1). Frequently updated information on influenza activity, influenza testing, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2019 Jan 14;61(1563):1-4 | Show Full IntroductionHide Full Introduction

Expanded Table: Antiviral Drugs for Treatment and Prophylaxis of Seasonal Influenza 2018-2019 (online only)

   
The Medical Letter on Drugs and Therapeutics • January 14, 2019;  (Issue 1563)
...
View the Expanded Table: Antiviral Drugs for Seasonal Influenza
Med Lett Drugs Ther. 2019 Jan 14;61(1563):e11-2 | Show Full IntroductionHide Full Introduction

Baloxavir Marboxil (Xofluza) for Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • December 3, 2018;  (Issue 1561)
The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients...
The FDA has approved baloxavir marboxil (Xofluza – Shionogi/Genentech), the first polymerase acidic (PA) endonuclease inhibitor, for single-dose, oral treatment of acute uncomplicated influenza in patients ≥12 years old. Baloxavir is the first drug with a new mechanism of action to be approved for treatment of influenza in almost 20 years.
Med Lett Drugs Ther. 2018 Dec 3;60(1561):193-6 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Seasonal Influenza 2017-2018

   
The Medical Letter on Drugs and Therapeutics • January 1, 2018;  (Issue 1537)
Antiviral drugs can be used for treatment and prophylaxis of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at...
Antiviral drugs can be used for treatment and prophylaxis of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2018 Jan 1;60(1537):1-4 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Seasonal Influenza 2016-2017

   
The Medical Letter on Drugs and Therapeutics • January 2, 2017;  (Issue 1511)
Antiviral drugs can be used for prophylaxis and treatment of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at...
Antiviral drugs can be used for prophylaxis and treatment of influenza. Frequently updated information on influenza activity, testing for influenza, and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2017 Jan 2;59(1511):1-3 | Show Full IntroductionHide Full Introduction

Antiviral Drugs for Seasonal Influenza 2015-2016

   
The Medical Letter on Drugs and Therapeutics • December 21, 2015;  (Issue 1484)
Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination1 for prophylaxis. Frequently updated information on influenza activity and antiviral resistance is...
Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination1 for prophylaxis. Frequently updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.
Med Lett Drugs Ther. 2015 Dec 21;57(1484):169-71 | Show Full IntroductionHide Full Introduction

Peramivir (Rapivab): An IV Neuraminidase Inhibitor for Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • February 2, 2015;  (Issue 1461)
The FDA has approved peramivir (Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had...
The FDA has approved peramivir (Rapivab – BioCryst), an IV neuraminidase inhibitor administered as a single dose, for treatment of acute uncomplicated influenza in patients ≥18 years old who have had symptoms for no more than 2 days. Peramivir was available temporarily in the US during the 2009-2010 influenza season under an emergency use authorization for treatment of hospitalized patients. It has been available in some Asian countries since 2010. Peramivir is the third neuraminidase inhibitor to be approved in the US. Oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, are approved for prophylaxis and treatment of influenza in children and adults.
Med Lett Drugs Ther. 2015 Feb 2;57(1461):17-9 | Show Full IntroductionHide Full Introduction

In Brief: Concerns about Oseltamivir (Tamiflu)

   
The Medical Letter on Drugs and Therapeutics • January 19, 2015;  (Issue 1460)
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk...
Some readers of our article on Antiviral Drugs for Seasonal Influenza have expressed concerns regarding our recommendation for use of the oral neuraminidase inhibitor oseltamivir (Tamiflu) to treat high-risk patients with confirmed or suspected influenza illness, citing the British Medical Journal and The Cochrane Collaboration, which have contended that there is no acceptable evidence that the drug prevents complications or hospitalizations and have questioned the completeness of the results of controlled trials conducted by the manufacturer (Roche).
Med Lett Drugs Ther. 2015 Jan 19;57(1460):14 | Show Full IntroductionHide Full Introduction